Alissa Abdulrahman, Alrashed Mohammed A, Alshaya Abdulrahman I, Al Sulaiman Khalid, Alharbi Shmeylan
Pharmaceutical Care Services, King Abdullah Bin Abdulaziz University Hospital, Riyadh, Saudi Arabia.
College of Pharmacy, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
Front Med (Lausanne). 2024 Oct 29;11:1476242. doi: 10.3389/fmed.2024.1476242. eCollection 2024.
Vitamin C (Ascorbic acid) has evolved as an emergent co-intervention for sepsis and septic shock patients. Multiple studies discussed the pathophysiological value of vitamin C to reserve endothelial functionality and improve microcirculatory flow in these patients. Nevertheless, most randomized clinical trials failed to show the clinical impact of adding vitamin C to sepsis and septic shock. Pneumonia is the most common infection to induce sepsis and septic shock, which could be an acute respiratory distress syndrome. Preliminary data support the role of vitamin C in mitigating the risk of acute respiratory distress syndrome (ARDS) development. This review aims to compare and contrast these trials and explore differences in their patients' populations, methodologies, and outcomes, emphasizing pneumonia-induced sepsis and septic shock.
维生素C(抗坏血酸)已成为脓毒症和脓毒性休克患者一种新出现的联合干预措施。多项研究探讨了维生素C在这些患者中保留内皮功能和改善微循环血流的病理生理价值。然而,大多数随机临床试验未能显示在脓毒症和脓毒性休克治疗中添加维生素C的临床效果。肺炎是诱发脓毒症和脓毒性休克最常见的感染,可能会发展为急性呼吸窘迫综合征。初步数据支持维生素C在降低急性呼吸窘迫综合征(ARDS)发生风险方面的作用。本综述旨在比较和对比这些试验,并探讨其患者群体、方法和结果的差异,重点关注肺炎诱发的脓毒症和脓毒性休克。